Effective as of January 19, 2022, Dr. Richard Gaster resigned from his position as a member of the Board of Directors (the Board") of Elevation Oncology, Inc. and from all committees of the Board on which he served. In connection with Dr. Gaster's resignation, the Board appointed Dr. Colin Walsh as a member of the Board's Audit Committee to fill the vacancy left by Dr. Gaster.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +2.78% | +10.30% | +657.91% |
05-14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
05-02 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+657.91% | 222M | |
+8.92% | 114B | |
+10.48% | 105B | |
-3.00% | 21.73B | |
-6.45% | 23.83B | |
-10.67% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Announces Board Changes